Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration‐resistant prostate cancer (CRPC)Sumanta K. Pal, Jeremy O. Jones|Cancer|2017Cited by 88
Clinical outcome in patients receiving systemic therapy for metastatic sarcomatoid renal cell carcinoma: A retrospective analysis☆Sumanta K. Pal, Clayton Lau, Robert A. Figlin et al.|Urologic Oncology Seminars and Original Investigations|2012Cited by 21
Supplementary Table 1 from RNA-seq Reveals Aurora Kinase–Driven mTOR Pathway Activation in Patients with Sarcomatoid Metastatic Renal Cell CarcinomaSumanta K. Pal, Jeremy O. Jones, Miaoling He et al.|Unknown|2023Cited by 0
Supplementary Table 3 from RNA-seq Reveals Aurora Kinase–Driven mTOR Pathway Activation in Patients with Sarcomatoid Metastatic Renal Cell CarcinomaSumanta K. Pal, Jeremy O. Jones, José A. Karam et al.|Unknown|2023Cited by 0